Risk of Fewer Evaluation-Testing Orders Due to a Decline in New Foods-With-Health-Claims Development Projects
First written in FY2016. 15 of 16 entries say "Restated". Latest entry: FY2024-Q2.
The whole theme swung hardest in 2017: 3 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2024-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2023RestatedAnnual report
「Recently, new development projects have continued to decline, partly because development of foods with health claims carrying general health claims, such as those relating to blood pressure and blood glucose levels, has largely run its course.」
The risk of a decline in new evaluation testing orders following the completion of development of FOSHU products with general health claims continues to be recognized. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2023-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2022-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2021-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2021-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2020RestatedAnnual report
「Recently, new development projects have continued to decline, partly because development of foods with health claims carrying general health claims, such as those relating to blood pressure and blood glucose levels, has largely run its course.」
The risk of a decline in new evaluation testing orders following the completion of development of FOSHU products with general health claims continues to be recognized. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is disclosed as having no material changes. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is collectively disclosed as having no material changes. - FY2019-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is collectively disclosed as having no material changes. - FY2019-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The risk to evaluation testing orders from a decline in new FOSHU development projects is collectively disclosed as having no material changes. - FY2018RestatedAnnual report
「Recently, new development projects have continued to decline, partly because development of foods with health claims carrying general health claims, such as those relating to blood pressure and blood glucose levels, has largely run its course.」
The risk of a decline in new evaluation testing orders following the completion of development of FOSHU products with general health claims continues to be recognized. - FY2016First statedAnnual report
「Recently, new development projects have continued to decline, partly because development of foods with health claims carrying general health claims, such as those relating to blood pressure and blood glucose levels, has largely run its course.」
The Company states that orders for the evaluation testing business are affected by customers' development capabilities and financial resources, management policies and budgets.